Get the Stockscreener App
3.70
5.71%
0.20
After Hours:
3.69
-0.01
-0.27%
X 4 Pharmaceuticals Inc stock is traded at $3.70, with a volume of 437.83K.
It is up +5.71% in the last 24 hours and up +1.09% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.50
Open:
$3.51
24h Volume:
437.83K
Relative Volume:
0.73
Market Cap:
$323.52M
Revenue:
$33.98M
Net Income/Loss:
$-95.10M
P/E Ratio:
-0.3697
EPS:
-10.0072
Net Cash Flow:
$-106.13M
1W Performance:
+13.85%
1M Performance:
+1.09%
6M Performance:
+5.71%
1Y Performance:
-66.49%
1-Day Range:
$3.42
$3.71
1-Week Range:
$3.20
$3.71
52-Week Range:
$1.35
$11.47
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.70 | 306.03M | 33.98M | -95.10M | -106.13M | -10.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - The Manila Times
XFOR Technical Analysis & Stock Price Forecast - Intellectia AI
X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
XFOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
Biotech X4 hires staff with stock options priced at $3.44 - Stock Titan
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
EMA backs potential first WHIM treatment in EU after 60% infection drop - Stock Titan
XFOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
X4 Pharmaceuticals (XFOR) Price Target Increased by 16.67% to 9.52 - Nasdaq
ETF Watch: How much upside does X4 Pharmaceuticals Inc haveJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Layoff Tracker: BMS, Catalent Further Whittle Workforces - BioSpace
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Final Week & Verified Chart Pattern Trade Signals - mfd.ru
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and SchizophreniaA New Chemical Entity Opening New Horizons in Psychiatric Innovation - Morningstar
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Tax-related stock sale by Rocket Pharma (RCKT) CEO Gaurav Shah - Stock Titan
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Artal Participations boosts Lexicon (NASDAQ: LXRX) stake with Series B preferred buy - Stock Titan
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
AI Stocks: Will CADL stock go up in YEAR2025 Risk Factors & Precise Trade Entry Recommendations - baoquankhu1.vn
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Can X4 Pharmaceuticals Inc. lead its sector in growthPortfolio Gains Summary & AI Based Trade Execution Alerts - mfd.ru
[SCHEDULE 13G/A] X4 Pharmaceuticals, Inc Amended Passive Investment Disclosure - Stock Titan
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
BVF group reports 3.9% X4 Pharmaceuticals (XFOR) stake via shares and warrants - Stock Titan
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is X4 Pharmaceuticals Inc. forming a bullish divergenceWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - TMX Newsfile
How X4 Pharmaceuticals Inc. stock trades before earningsQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
XFOR Should I Buy - Intellectia AI
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - stocktitan.net
Insider Returns Down To US$57k As X4 Pharmaceuticals' Stock Dips 11% - simplywall.st
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
X4 Pharmaceuticals: Commercial Execution Takes Center Stage - AD HOC NEWS
Aug Gainers: Can X4 Pharmaceuticals Inc sustain earnings growthWall Street Watch & Entry Point Confirmation Alerts - baoquankhu1.vn
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):